DC-CIK免疫治疗对卵巢癌患者凝血功能及D-二聚体水平的影响

doi:10.13481/j.1671-587x.20170124

吉林大学学报(医学版) ›› 2017, Vol. 43 ›› Issue (01): 120-124.doi: 10.13481/j.1671-587x.20170124

DC-CIK免疫治疗对卵巢癌患者凝血功能及D-二聚体水平的影响

王睿斌¹, 赫东芸², 邹积艳², 盛敏佳²

1. 首都医科大学附属北京世纪坛医院急诊科, 北京 100038;
2. 吉林大学中日联谊医院妇产科, 吉林长春 130033

收稿日期:2016-08-02 出版日期:2017-01-28 发布日期:2017-02-08
通讯作者: 盛敏佳,副主任医师,硕士研究生导师(Tel:0431-84995752,E-mail:minjia-sheng@hotmail.com) E-mail:minjia-sheng@hotmail.com
作者简介:王睿斌(1974-),男,北京市人,主治医师,医学硕士,主要从事肿瘤治疗及急诊方面的研究。
基金资助:
吉林省科技厅科研基金资助课题（20150414036GH）

Influence of DC-CIK immunotherapy in blood coagulation function and D-dimer levels in patients with ovarian cancer

WANG Ruibin¹, HE Dongyun², ZOU Jiyan², SHENG Minjia²

1. Department of Emergency, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;
2. Department of Obstetris and Gynecology, China-Japan Union Hospital, Jilin University, Changchun 130033, China

Received:2016-08-02 Online:2017-01-28 Published:2017-02-08

摘要/Abstract

摘要：

目的：探讨树突状细胞诱导的杀伤细胞（DC-CIK）免疫治疗前后卵巢癌患者凝血功能指标及D-二聚体水平的变化，并阐明其临床意义。方法：选择行DC-CIK治疗的40例卵巢癌患者，在粒细胞集落刺激因子（G-CSF）动员前5 d及DC-CIK免疫治疗1个月后行凝血功能各指标及D-二聚体水平的检测。比较卵巢癌患者DC-CIK免疫治疗前后凝血功能及D-二聚体水平的差异。结果：DC/CIK细胞回输后卵巢癌患者D-二聚体水平从1063μg·L^-1降至485μg·L^-1，纤维蛋白原（FIB）水平降低10%，DC/CIK治疗前后D-二聚体和FIB水平比较差异有统计学意义（P<0.05）。在Ⅳ期卵巢癌患者及>60岁卵巢癌患者中D-二聚体和FIB水平降低程度更为明显。与治疗前比较，治疗后D-二聚体水平正常（<243μg·L^-1）患者比例明显增加（P<0.05）。结论：DC-CIK免疫治疗可通过降低卵巢癌患者的D-二聚体及FIB水平，降低其静脉血栓风险。

关键词: 树突状细胞诱导的杀伤细胞, 凝血功能, D-二聚体, 卵巢肿瘤, 免疫治疗

Abstract:

Objective: To investigate the changes of blood coagulation function and D-dimer levels in the ovarian cancer patients before and after dentritic cells-cytokine-induced killer cells (DC-CIK) immunotherapy, and to clarify its clinical significance.Methods: Forty ovarian cancer patients treated with DC-CIK immunotherapy were selected. The indicators of blood coagulation function and the D-dimer levels. 5 d before G-CSF mobilization and 1 month after DC-CIK immunotherapy were detected. The differences in the blood coagulation function and D-dimer levels of the ovarian cancer patients were compared between before and after DC-CIK immunotherapy.Results: The D-dimer level of the ovarian cancer patients was decreased from 1063μg·L^-1 to 485μg·L^-1 after DC/CIK cell reinfusion (P<0.05), and the fibrinogen(FIB) level was decreased by 10%(P<0.05). The changes were more significant in the ovarian cancer patients at Ⅳstage (FIB) and the patients aged over 60 years old. Compared with before treatment,the proption of ovarian cancer patients with normal D-dimer level (<243μg·L^-1) after treatment was increased(P<0.05).Conclusion: DC-CIK immunotherapy can reduce the levels of D-dimer and FIB in the ovarian cancer patients, and also reduce the risk of venous thrombosis.

Key words: dentritic cells-cytokine-induced killer cells, blood coagulation function, D-dimer, ovarian neoplasm, immunotherapy

中图分类号:

R737.31

王睿斌, 赫东芸, 邹积艳, 盛敏佳. DC-CIK免疫治疗对卵巢癌患者凝血功能及D-二聚体水平的影响[J]. 吉林大学学报(医学版), 2017, 43(01): 120-124.

WANG Ruibin, HE Dongyun, ZOU Jiyan, SHENG Minjia. Influence of DC-CIK immunotherapy in blood coagulation function and D-dimer levels in patients with ovarian cancer[J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 120-124.

参考文献

[1] Faiz AS, Khan I, Beckman MG, et al. Characteristics and risk factors of cancer associated venous thromboembolism[J].Thromb Res, 2015,136(3):535-541.
[2] Couzin-Frankel J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science, 2013,342(6165):1432-1433.
[3] Dammacco F, Vacca A, Procaccio P, et al. Cancer-related coagulopathy (Trousseau's syndrome):review of the literature and experience of a single center of internal medicine[J].Clin Exp Med, 2013,13(2):85-97.
[4] Tas F,Ciftci R, Kilic L, et al. Clinical and prognostic significance of coagulation assays in melanoma[J].Melanoma Res,2012,22(5):368-395.
[5] Liu P, Zhu Y, Liu L. Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma[J].Oncol Targets Ther, 2015, 4(8):1335-1340.
[6] Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer[J]. Oncology, 2012,83(1):10-15.
[7] Inanc M, Er O, Karaca H, et al. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer[J]. BUON, 2013,18(2):391-397.
[8] Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression[J]. Breast Cancer Res, 2013,15(4):207.
[9] Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer:a systematic review and meta-analysis[J]. Int J Clin Exp Med, 2015,8(4):5379-5387.
[10] Khalil J, Bensaid B, Elkacemi H,et al. Venous thromboembolism in cancer patients:an underestimated major health problem[J]. World J Surg Oncol, 2015,13:204.
[11] Afshar M, Hamilton P, Seligmann J, et al. Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)[J]. Cancer Invest, 2015,33(8):347-353.
[12] Rhode S, Paul MC, Martens E, et al. Simulation of haemodynamic flow in head and neck cancer chemotherapy[J].Biomed Eng Online, 2011,10:104.
[13] Bremm M, Huenecke S, Zimmermann O, et al. In-vitro influence of mycophenolate mofetil (MMF) and ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy[J].J Transl Med, 2016,14:264.
[14] Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients[J]. Cancer Immunol Immunother, 2013,62(1):65-73.
[15] Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer[J]. Int Immunopharmacol, 2015,28(1):22-28.
[16] Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer:reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788.
[17] Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma[J]. Chin Med J, 2012,125(21):3771-3777.
[18] Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology, 2015,148(7):1383-1391.

DC-CIK免疫治疗对卵巢癌患者凝血功能及D-二聚体水平的影响

Influence of DC-CIK immunotherapy in blood coagulation function and D-dimer levels in patients with ovarian cancer

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	孙洪帅, 朱华, 高海燕, 万广财, 于秀艳. 肿瘤标志物SCC-Ag、CEA、CYFRA21-1和D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J]. 吉林大学学报(医学版), 2018, 44(05): 1020-1024.
[2]	梁冰, 刘扬, 宋金萍, 曲丹华, 刘纯岩. 组蛋白去乙酰化酶抑制剂SAHA对卵巢癌SKOV3细胞的化疗增敏作用[J]. 吉林大学学报(医学版), 2018, 44(03): 471-476.
[3]	上官梦原, 赵菁, 杨艳荣, 张佳悦, 陈俊宇, 赵淑华. 五味子脂A联合卡铂对人卵巢癌Skov3细胞增殖、迁移和侵袭的抑制作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(02): 292-298.
[4]	钟莉莉, 赵银龙, 李炳锦, 邹晓晗, 程子倩, 崔然吉. MicroRNA-210对卵巢癌细胞生长及放射敏感性的影响[J]. 吉林大学学报(医学版), 2018, 44(02): 265-269.
[5]	上官梦原, 赵菁, 陈俊宇, 杨艳荣, 张佳悦, 赵淑华. 五味子脂A增强卡铂对人卵巢癌Skov3细胞的促凋亡作用及其机制[J]. 吉林大学学报(医学版), 2018, 44(01): 83-89.
[6]	王雪, 秦瑞, 王皓莹, 高守阳, 兰彦方, 田秀娟. 乳胞素联合卡铂对卵巢癌SKOV3细胞的增殖抑制作用和促凋亡作用[J]. 吉林大学学报(医学版), 2017, 43(06): 1098-1102.
[7]	原颖丽, 撒焕兰, 马克威. 横纹肌肉瘤的诊断及治疗研究进展[J]. 吉林大学学报(医学版), 2017, 43(05): 1059-1063.
[8]	赫东芸, 王立岩, 盛敏佳. 预防性输卵管切除术对卵巢功能的影响及其对盆腔疾病的预防作用[J]. 吉林大学学报(医学版), 2017, 43(03): 635-639.
[9]	王立岩, 张贝贝, 赫东芸, 盛敏佳, 王雪. 二甲双胍和紫杉醇对卵巢癌SKOV3细胞体外增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2017, 43(02): 255-259.
[10]	王迦南, 冯辉, 王倩, 何悦铭, 宋艳秋, 朱继红. 自然杀伤细胞联合他莫昔芬对乳腺癌细胞的杀伤作用及其机制[J]. 吉林大学学报(医学版), 2017, 43(02): 281-287.
[11]	汪海娇, 范艳艳, 张湜, 张瑞丽, 张海静, 韩亚辉, 朱继红. γδT细胞对卵巢癌SKOV3细胞增殖的抑制作用[J]. 吉林大学学报(医学版), 2016, 42(05): 897-900.
[12]	盛敏佳, 刘津, 刘俊宝, 邹积艳. 褪黑素联合卡铂对卵巢癌SKOV3细胞体外增殖及凋亡的影响[J]. 吉林大学学报(医学版), 2016, 42(01): 70-75.
[13]	王堃, 张爱臣, 盛敏佳, 潘颖, 佟玲玲, 孙小淳. 骨桥蛋白和趋化因子受体4在卵巢肿瘤组织中的表达及其意义[J]. 吉林大学学报(医学版), 2015, 41(06): 1186-1189.
[14]	于洋, 刘亚萌, 吴少花, 谢奇, 衣丹, 徐海月, 胡耀狄, 陈君, 徐冶. 杨梅素对人卵巢癌SKOV3细胞的凋亡诱导作用[J]. 吉林大学学报(医学版), 2015, 41(05): 902-906.
[15]	王珂, 邹积艳, 汪丽, 杜珍武, 王俊容, 叶聪, 潘颖. RhoC慢病毒干扰载体的构建及其对卵巢癌SKOV3细胞中RhoC mRNA表达的影响[J]. 吉林大学学报(医学版), 2015, 41(02): 304-306.